Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jan 28;3(2):323-344.
doi: 10.3390/ph3020323.

Oromucosal Administration of Interferon to Humans

Manfred W Beilharz  1 , Martin J Cummins  2 , Alayne L Bennett  3 , Joseph M Cummins  4
Affiliations
Review

Oromucosal Administration of Interferon to Humans

Manfred W Beilharz et al. Pharmaceuticals (Basel). .

Abstract

The prevailing dogma is that, to be systemically effective, interferon-alpha (IFNα) must be administered in sufficiently high doses to yield functional blood concentrations. Such an approach to IFNa therapy has proven effective in some instances, but high-dose parenteral IFNα therapy has the disadvantage of causing significant adverse events. Mounting evidence suggests that IFNα delivered into the oral cavity in low doses interacts with the oral mucosa in a unique manner to induce systemic host defense mechanisms without IFNα actually entering the circulation, thus reducing the potential for toxic side effects. A better understanding of the applications and potential benefits of this treatment modality are under active investigation. This paper provides a review of the relevant literature on the clinical use of the oromucosal route of administration of interferon, with an emphasis on the treatment of influenza.

Keywords: influenza; interferon; oromucosal delivery; treatment; viral diseases.

PubMed Disclaimer

References

    1. Hopps H.E., Zoon K.C., Djeu J.Y., Petricciani J.C. Interferons For Clinical Use: Purity, Potency And Safety. In: Finter N.B., Oldham R.K., editors. Interferon. Vol. 4. Elsevier Science Publishers; Amsterdam, The Netherlands: 1985. pp. 121–133.
    1. Bocci V. Distribution, Catabolism and Pharmacokinetics of Interferons. In: Finter N.B., Oldham R.K., editors. Interferon. Vol. 4. Elsevier Science Publishers; Amsterdam, The Netherlands: 1985. pp. 47–72.
    1. Langford M.P., Stanton G.J. Role of Interferon in Ocular Viral Disease. In: Baron S., Ferdinando D., Stanton G.J., Fleischmann W.R. Jr., editors. The Interferon System,a Current Review to 1987. The University of Texas Press; Austin, TX, USA: 1987. pp. 453–459.
    1. Baron S., Tyring S.K., Fleischmann W.R., Jr., Coppenhaver D.H., Niesel D.W., Klimpel G.R., Stanton G.J., Hughes T.K. The interferons. Mechanisms of action and clinical applications. JAMA. 1991;266:1375–1383. - PubMed
    1. Strander H. Toxicities of. Interferons. In: Stuart-Harris R., Penny R., editors. Clinical Applications of the Interferons. Chapman & Hall Medical; London, UK: 1997. pp. 331–363.

LinkOut - more resources